92.8%
of oral medications contain at least one inactive ingredient linked to allergic reactions.
Science Translational Medicine, 2019
The invisible half of the drug label
The prescription didn’t change. The patient’s reaction says otherwise.
Same drug, same dose, different manufacturer — and a different set of dyes, binders, and preservatives. ExciIQ makes the inactive ingredients in every FDA-labeled medication visible, comparable, and searchable.
Professional use only — not for patient diagnosis or treatment decisions.
Excipients are the blind spot of medication review.
Patients react to inactive ingredients — dyes, gluten, lactose, preservatives, binders — and finding the culprit across a multi-drug regimen is manual label archaeology. The answer is buried across hundreds of thousands of public FDA labels, and the same drug can differ by manufacturer and even by strength.
8.8
inactive ingredients in the average oral medication — 45% contain lactose, 33% an FD&C dye.
Science Translational Medicine, 2019
39%
of drug labels audited carried internally inconsistent excipient lists — the label disagrees with itself.
Naunyn-Schmiedeberg's Archives of Pharmacology, 2024
And the ground keeps moving: FDA retired its public pill-identification database in 2021 without a replacement, and the 2025 ban on FD&C Red No. 3 has drug formulations changing between now and 2028. ExciIQ was built to end the archaeology.
Built for clinicians whose names go on the decision.
See the whole regimen’s excipient load.
Assemble a patient’s medications into a private workspace and see every excipient across the regimen — with per-excipient daily and weekly intake totals and a regimen-wide comparison matrix. Not just “present”: how often it’s swallowed. Identified only by a memorable session code, gender, and derived age: never patient data, because ExciIQ holds none.
Turn “we don’t know why” into a shortlist.
Sort medications into tolerated Friends and reaction-associated Foes; ExciIQ surfaces the suspect excipients unique to the Foes — and flags Top Suspects present in every one of them. Save the workup and pick it up where you left off.
Alternatives you can defend — with receipts.
Choose the excipients to avoid, and ExciIQ finds therapeutic equivalents with three honest verdicts. Uncertain is never dressed up as safe — that distinction is the whole point.
A label database that admits what it doesn’t know.
Every record carries provenance — where it came from and its review status — and when a drug’s coded ingredient list disagrees with its written label text, ExciIQ shows you the difference side by side, in plain language. Every claim sits one click from its FDA label record. “Not yet reviewed” is always distinct from “reviewed, nothing found” — because a clinician’s trust has to be earned on every record, not claimed once.
The reference desk for inactive ingredients.
Look up any excipient and get a working reference card: identifiers, functions, cautions, and which products contain it. Search medications by name or NDC, identify pills by imprint, color, and shape, and read the structured FDA label without wading through the raw document.
Precise to the product on the shelf.
The same drug can carry different excipients by manufacturer — and even by strength. ExciIQ keeps its analysis at the level of the specific product in the bottle, because a 20 mg tablet’s dye list can’t answer a question about the 40 mg.
Professional use only — not for patient diagnosis or treatment decisions.
Trust, then verify
Nothing to breach. Nothing to hide.
ExciIQ holds no patient data — by architecture, not policy. Regimens live under a memorable session code with gender and derived age only. Sign-in is passwordless. And the honesty extends to the data itself: provenance on every record, disagreements shown instead of smoothed over, every claim one click from its FDA label record. Even our alerts are marigold, not red — designed to inform your judgment, never to alarm it.
How we earn trust →Three ways in.
Founding seat
We’re onboarding a small founding cohort of compounding and community pharmacists — and the allergy-focused physicians and hospital pharmacists they work with. You bring the real cases; we build to them — with a direct line to the founder.
Apply for a founding seatFifteen honest minutes
Fifteen minutes, one regimen, no slides. We’ll walk a workup on common over-the-counter examples — and we’ll show you what it looks like when the honest answer is “uncertain.” Your own case is the first thing we do together once you’re in the pilot.
Book fifteen honest minutesThe briefing
The Excipient Blind Spot is a short, occasional email on excipient awareness for pharmacy and medical professionals — plain language, public-knowledge examples, the same honest voice.
Get the briefing